Curative effectiveness of sirolimus applied after liver transplantation for hepatocellular carcinoma:a systematic review
10.3760/cma.j.issn.0254-1785.2018.07.008
- VernacularTitle:西罗莫司应用于肝癌肝移植后疗效的系统评价
- Author:
Hongliang WANG
1
;
Xuyong SUN
;
Jianhui DONG
;
Liugen LAN
;
Ke QIN
;
Jihua WU
;
Haibin LI
;
Zhuangjiang LI
Author Information
1. 解放军第三○三医院移植医学研究院 广西移植医学重点实验室 广西移植医学工程技术研究中心
- Keywords:
Hepatocellular carcinoma;
Liver transplantation;
Sirolimus;
Systematic review
- From:
Chinese Journal of Organ Transplantation
2018;39(7):418-424
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of sirolimus (SRL) after liver transplantation for hepatocellular carcinoma (HCC).Methods The information up to January 2018 was retrieved from Cochrane library,Pubmed,EMbase,CBM,CNKI,VIP.Collected publications were all about casecontrol study of SRL versus calcineurin inhibitors (CNIs) after liver transplantation for HCC.After evaluating the literatures' quality and extracting the data,RevMan 5.3 was used to analyze the data of each study.Results A total of 13 articles including 4181 patients were enrolled.There was no significant difference between SRL and CNIs in 3 and 5 year diseasefree survival (RR=1.13,95％CI:0.97-1.31,P=0.11;RR=1.07,95%CI:0.92-1.24,P=0.37),however,the 1-,3-and 5-year overall survival rate and 1-year disease-free survival rate in SRL were significantly higher than CNIs (RR=1.09,95％CI.:1.03-1.15,P=0.005;RR=1.08,95％CI:1.02-1.14,P =0.006;RR =1.11,95％CI:1.00-1.23,P =0.05;RR=1.14,95％CI:1.05-1.24,P =0.001).Conclusion There was no significant difference between SRL and CNIs in 3-and 5-year disease-free survival,but the 1-,3-and 5-year overall rate and 1-year disease-free survival rate in SRL was significantly higher than in CNIs.
